Vector-Borne Diseases

2

Review clinical trials related to Vector-Borne Diseases. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing

Background: Vector-borne diseases are caused by the bite of an infected mosquito, fly, flea, tick, or other blood-feeder. These diseases cause almost 1 million deaths per year. And they are on the rise, particularly in Southeast Asia in particular. Researchers think that these diseases make up about 10 percent of fevers in Cambodia. But many of these illnesses are never diagnosed. Studying these diseases can help find new ways to identify and treat them. Objective: To find pathogens in people who have a fever using metagenomic pathogen sequencing platforms. Eligibility: People aged 2 months to 65 years with a fever of at least 38 degrees Celsius or those diagnosed with infection by a pathogen of concern who visit the referral hospital in Cambodia. Close contacts of people diagnosed with infection by a pathogen of concern may also be enrolled. Design: Participants will be screened with their medical history. Children will be weighed to make sure they are big enough to give blood samples. Participants will share data about their sex, age, and where they live. They will answer more questions about their heath history. They will answer questions about and any places to which they have recently traveled. They will take a questionnaire. They will have a blood test. If they have respiratory symptoms, they will have a nasal swab. Participants may be contacted within 1-2 weeks (early) and/or within 3 months (late) from their enrollment date to provide an optional follow-up blood samples and nasal swabs....

Participants needed: 6,500
Trial details
Age: 2-65Biological sex: AllType: ObservationalSponsor: National Institute of Allergy and Infectious Diseases (NIAID)Updated: Jun 24, 2026Locations: 6
Eligibility criteria

Provision of signed and dated informed consent form. [+6]

Any underlying, chronic, or current medical condition that, in the opinion of th... [+2]

Status: Not yet recruiting

Therapeutics for Moderate and Severe Dengue

The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.

Participants needed: 8,800
Trial details
Phase: Phase 3Age: 5+Biological sex: AllType: InterventionalSponsor: Oxford University Clinical Research Unit, VietnamUpdated: Apr 21, 2026Locations: 18
Eligibility criteria

Age ≥5 years [+14]

Patients on ≥ day 10 of illness or who are clinically improving in the opinion o... [+1]